Howard Levy's most recent trade in Catalyst Biosciences Inc was a trade of 639 Common Stock done at an average price of $3.6 . Disclosure was reported to the exchange on Aug. 9, 2021.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Catalyst Biosciences Inc | Howard Levy | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 3.62 per share. | 09 Aug 2021 | 639 | 639 (0%) | 0% | 3.6 | 2,313 | Common Stock |
Catalyst Biosciences Inc | Howard Levy | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 4.81 per share. | 09 Feb 2021 | 1,670 | 23,390 (0%) | 0% | 4.8 | 8,033 | Common Stock |
Catalyst Biosciences Inc | Howard Levy | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
Catalyst Biosciences Inc | Howard Levy | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 4.81 per share. | 10 Aug 2020 | 1,768 | 4,268 (0%) | 0% | 4.8 | 8,504 | Common Stock |